Furazolidone-based triple therapy for H pylori gastritis in children

Detalhes bibliográficos
Autor(a) principal: Kawakami, Elisabete [UNIFESP]
Data de Publicação: 2006
Outros Autores: Machado, Rodrigo Strehl [UNIFESP], Ogata, Silvio Kazuo [UNIFESP], Langner, Marini [UNIFESP], Fukushima, Erika [UNIFESP], Carelli, Anna Paula [UNIFESP], Bonucci, Vania Claudia Guimaraes [UNIFESP], Patricio, Francy Reis Silva [UNIFESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://repositorio.unifesp.br/11600/45741
http://dx.doi.org/10.3748/WJG.v12.i34.5544
Resumo: AIM: To evaluate the furazolidone-based triple therapy in children with symptomatic H pylori gastritis.METHODS: A prospective and consecutive open trial was carried out. The study included 38 patients with upper digestive symptoms sufficiently severe to warrant endoscopic investigation. H pylori status was defined based both on histology and on positive C-13-urea breath test. Drug regimen was a seven-day course of omeprazole, clarithromycin and furazolidone (100 mg, 200 mg if over 30 kg) twice daily. Eradication of H pylori was assessed two months after treatment by histology and C-13-urea breath test. Further clinical evaluation was performed 7 cl, 2 and 6 mo after the treatment.RESULTS: Thirty-eight patients (24 females, 14 males) were included. Their age ranged from 4 to 17.8 (mean 10.9 +/- 3.7) years. On intent-to-treat analysis (n = 38), the eradication rate of H pylori was 73.7% (95% CI, 65.2%-82%) whereas in per-protocol analysis (n = 33) it was 84.8% (95% CI,. 78.5%-91%)., All the patients with duodenal ulcer (n = 7) were successfully treated (100% vs 56.2% with antral nodularity). Side effects were reported in 26 patients (68.4%), mainly vomiting (14/26) and abdominal pain (n = 13). Successfully treated dyspeptic patients showed improvement in 78.9% of H pylori-negative patients after six months and in 50% of H pylori-positive patients after six months of treatment.CONCLUSION: Triple therapy with furazolidone achieves moderate efficacy in H pylori treatment. The eradication rate seems to be higher in patients with duodenal ulcer. (C) 2006 The WJG Press. All rights reserved.
id UFSP_162b01f92db9b8caaee5821f0c2d56dc
oai_identifier_str oai:repositorio.unifesp.br:11600/45741
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Kawakami, Elisabete [UNIFESP]Machado, Rodrigo Strehl [UNIFESP]Ogata, Silvio Kazuo [UNIFESP]Langner, Marini [UNIFESP]Fukushima, Erika [UNIFESP]Carelli, Anna Paula [UNIFESP]Bonucci, Vania Claudia Guimaraes [UNIFESP]Patricio, Francy Reis Silva [UNIFESP]Universidade Federal de São Paulo (UNIFESP)2018-06-18T12:15:15Z2018-06-18T12:15:15Z2006-09-14World Journal Of Gastroenterology. Beijing: W J G Press, v. 12, n. 34, p. 5544-5549, 2006.1007-9327http://repositorio.unifesp.br/11600/45741http://dx.doi.org/10.3748/WJG.v12.i34.5544WOS000240647100020.pdf10.3748/WJG.v12.i24.3891WOS:000240647100020AIM: To evaluate the furazolidone-based triple therapy in children with symptomatic H pylori gastritis.METHODS: A prospective and consecutive open trial was carried out. The study included 38 patients with upper digestive symptoms sufficiently severe to warrant endoscopic investigation. H pylori status was defined based both on histology and on positive C-13-urea breath test. Drug regimen was a seven-day course of omeprazole, clarithromycin and furazolidone (100 mg, 200 mg if over 30 kg) twice daily. Eradication of H pylori was assessed two months after treatment by histology and C-13-urea breath test. Further clinical evaluation was performed 7 cl, 2 and 6 mo after the treatment.RESULTS: Thirty-eight patients (24 females, 14 males) were included. Their age ranged from 4 to 17.8 (mean 10.9 +/- 3.7) years. On intent-to-treat analysis (n = 38), the eradication rate of H pylori was 73.7% (95% CI, 65.2%-82%) whereas in per-protocol analysis (n = 33) it was 84.8% (95% CI,. 78.5%-91%)., All the patients with duodenal ulcer (n = 7) were successfully treated (100% vs 56.2% with antral nodularity). Side effects were reported in 26 patients (68.4%), mainly vomiting (14/26) and abdominal pain (n = 13). Successfully treated dyspeptic patients showed improvement in 78.9% of H pylori-negative patients after six months and in 50% of H pylori-positive patients after six months of treatment.CONCLUSION: Triple therapy with furazolidone achieves moderate efficacy in H pylori treatment. The eradication rate seems to be higher in patients with duodenal ulcer. (C) 2006 The WJG Press. All rights reserved.Univ Fed Sao Paulo, Escola Paulista Med, Dept Pediat,Pediat Gastroenterol Div, Pept Dis Outpatient Clin, Sao Paulo, BrazilUniv Fed Sao Paulo, Escola Paulista Med, Dept Pathol, Sao Paulo, BrazilUniv Fed Sao Paulo, Escola Paulista Med, Dept Pediat,Pediat Gastroenterol Div, Pept Dis Outpatient Clin, Sao Paulo, BrazilUniv Fed Sao Paulo, Escola Paulista Med, Dept Pathol, Sao Paulo, BrazilWeb of Science5544-5549engW J G PressWorld Journal Of GastroenterologyFurazolidoneH pylori treatmentgastritisChildrenFurazolidone-based triple therapy for H pylori gastritis in childreninfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP11600/457412022-09-19 22:26:18.41metadata only accessoai:repositorio.unifesp.br:11600/45741Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-05-25T12:38:05.465172Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.en.fl_str_mv Furazolidone-based triple therapy for H pylori gastritis in children
title Furazolidone-based triple therapy for H pylori gastritis in children
spellingShingle Furazolidone-based triple therapy for H pylori gastritis in children
Kawakami, Elisabete [UNIFESP]
Furazolidone
H pylori treatment
gastritis
Children
title_short Furazolidone-based triple therapy for H pylori gastritis in children
title_full Furazolidone-based triple therapy for H pylori gastritis in children
title_fullStr Furazolidone-based triple therapy for H pylori gastritis in children
title_full_unstemmed Furazolidone-based triple therapy for H pylori gastritis in children
title_sort Furazolidone-based triple therapy for H pylori gastritis in children
author Kawakami, Elisabete [UNIFESP]
author_facet Kawakami, Elisabete [UNIFESP]
Machado, Rodrigo Strehl [UNIFESP]
Ogata, Silvio Kazuo [UNIFESP]
Langner, Marini [UNIFESP]
Fukushima, Erika [UNIFESP]
Carelli, Anna Paula [UNIFESP]
Bonucci, Vania Claudia Guimaraes [UNIFESP]
Patricio, Francy Reis Silva [UNIFESP]
author_role author
author2 Machado, Rodrigo Strehl [UNIFESP]
Ogata, Silvio Kazuo [UNIFESP]
Langner, Marini [UNIFESP]
Fukushima, Erika [UNIFESP]
Carelli, Anna Paula [UNIFESP]
Bonucci, Vania Claudia Guimaraes [UNIFESP]
Patricio, Francy Reis Silva [UNIFESP]
author2_role author
author
author
author
author
author
author
dc.contributor.institution.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
dc.contributor.author.fl_str_mv Kawakami, Elisabete [UNIFESP]
Machado, Rodrigo Strehl [UNIFESP]
Ogata, Silvio Kazuo [UNIFESP]
Langner, Marini [UNIFESP]
Fukushima, Erika [UNIFESP]
Carelli, Anna Paula [UNIFESP]
Bonucci, Vania Claudia Guimaraes [UNIFESP]
Patricio, Francy Reis Silva [UNIFESP]
dc.subject.eng.fl_str_mv Furazolidone
H pylori treatment
gastritis
Children
topic Furazolidone
H pylori treatment
gastritis
Children
description AIM: To evaluate the furazolidone-based triple therapy in children with symptomatic H pylori gastritis.METHODS: A prospective and consecutive open trial was carried out. The study included 38 patients with upper digestive symptoms sufficiently severe to warrant endoscopic investigation. H pylori status was defined based both on histology and on positive C-13-urea breath test. Drug regimen was a seven-day course of omeprazole, clarithromycin and furazolidone (100 mg, 200 mg if over 30 kg) twice daily. Eradication of H pylori was assessed two months after treatment by histology and C-13-urea breath test. Further clinical evaluation was performed 7 cl, 2 and 6 mo after the treatment.RESULTS: Thirty-eight patients (24 females, 14 males) were included. Their age ranged from 4 to 17.8 (mean 10.9 +/- 3.7) years. On intent-to-treat analysis (n = 38), the eradication rate of H pylori was 73.7% (95% CI, 65.2%-82%) whereas in per-protocol analysis (n = 33) it was 84.8% (95% CI,. 78.5%-91%)., All the patients with duodenal ulcer (n = 7) were successfully treated (100% vs 56.2% with antral nodularity). Side effects were reported in 26 patients (68.4%), mainly vomiting (14/26) and abdominal pain (n = 13). Successfully treated dyspeptic patients showed improvement in 78.9% of H pylori-negative patients after six months and in 50% of H pylori-positive patients after six months of treatment.CONCLUSION: Triple therapy with furazolidone achieves moderate efficacy in H pylori treatment. The eradication rate seems to be higher in patients with duodenal ulcer. (C) 2006 The WJG Press. All rights reserved.
publishDate 2006
dc.date.issued.fl_str_mv 2006-09-14
dc.date.accessioned.fl_str_mv 2018-06-18T12:15:15Z
dc.date.available.fl_str_mv 2018-06-18T12:15:15Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv World Journal Of Gastroenterology. Beijing: W J G Press, v. 12, n. 34, p. 5544-5549, 2006.
dc.identifier.uri.fl_str_mv http://repositorio.unifesp.br/11600/45741
http://dx.doi.org/10.3748/WJG.v12.i34.5544
dc.identifier.issn.none.fl_str_mv 1007-9327
dc.identifier.file.none.fl_str_mv WOS000240647100020.pdf
dc.identifier.doi.none.fl_str_mv 10.3748/WJG.v12.i24.3891
dc.identifier.wos.none.fl_str_mv WOS:000240647100020
identifier_str_mv World Journal Of Gastroenterology. Beijing: W J G Press, v. 12, n. 34, p. 5544-5549, 2006.
1007-9327
WOS000240647100020.pdf
10.3748/WJG.v12.i24.3891
WOS:000240647100020
url http://repositorio.unifesp.br/11600/45741
http://dx.doi.org/10.3748/WJG.v12.i34.5544
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.none.fl_str_mv World Journal Of Gastroenterology
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 5544-5549
dc.publisher.none.fl_str_mv W J G Press
publisher.none.fl_str_mv W J G Press
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv
_version_ 1783460318748344320